Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	4.01
Equity-to-Asset	0.79
Debt-to-Equity	0.1
Debt-to-EBITDA	0.58
Interest Coverage	57.99
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	10.96	Distress Grey Safe
Beneish M-Score	-2.51	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	16
	3-Year EBITDA Growth Rate	5
	3-Year EPS without NRI Growth Rate	7.9
	3-Year FCF Growth Rate	22.8
	3-Year Book Growth Rate	32.1
	Future 3-5Y EPS without NRI Growth Rate	7.36
	Future 3-5Y Total Revenue Growth Rate	9.85

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	41.49
	9-Day RSI	37.7
	14-Day RSI	37.72
	6-1 Month Momentum %	20.79
	12-1 Month Momentum %	25.72

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.69
	Quick Ratio	4.94
	Cash Ratio	3.17
	Days Inventory	501.6
	Days Sales Outstanding	149.26
	Days Payable	115.75

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.8
	Shareholder Yield %	2.16

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	86.16
	Operating Margin %	32.27
	Net Margin %	30.14
	FCF Margin %	27.98
	ROE %	16.33
	ROA %	12.74
	ROIC %	21.07
	ROC (Joel Greenblatt) %	46.93
	ROCE %	15.39
	Years of Profitability over Past 10-Year	10

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	25.99
	Forward PE Ratio	20.01
	PE Ratio without NRI	22.51
	Shiller PE Ratio	32.96
	Price-to-Owner-Earnings	37.35
	PEG Ratio	1.27
	PS Ratio	7.83
	PB Ratio	3.8
	Price-to-Tangible-Book	3.96
	Price-to-Free-Cash-Flow	28.01
	Price-to-Operating-Cash-Flow	22.36
	EV-to-EBIT	21.38
	EV-to-Forward-EBIT	16.91
	EV-to-EBITDA	19.47
	EV-to-Forward-EBITDA	16.04
	EV-to-Revenue	6.96
	EV-to-Forward-Revenue	6.49
	EV-to-FCF	24.91
	Price-to-Projected-FCF	1.51
	Price-to-DCF (Earnings Based)	0.72
	Price-to-DCF (FCF Based)	0.9
	Price-to-Median-PS-Value	0.99
	Price-to-Peter-Lynch-Fair-Value	1.01
	Price-to-Graham-Number	2.04
	Price-to-Net-Current-Asset-Value	7.99
	Price-to-Net-Cash	26.43
	Earnings Yield (Greenblatt) %	4.68
	FCF Yield %	3.69
	Forward Rate of Return (Yacktman) %	23.38

GF Value: €666.87

WBO:REGN

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with REGN. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.